Patients with lymphoma receiving B-Cell–depleting therapies may be at greater risk for persistent COVID-19 infection
9 Feb, 2021 | 01:14h | UTCRelated: Patients on Active Chemotherapy May Not Be at Increased Risk for COVID-19 Infection – The ASCO Post
See also: Anti-CD20 Drugs Tied to Severe COVID in Cancer Patients — Plus: Active chemo treatment may not be a COVID risk factor – MedPage Today (free registration required)